Grace Therapeutics (GRCE) Interest & Investment Income (2019 - 2026)
Grace Therapeutics (GRCE) posted Interest & Investment Income of $138000.0 for Q1 2026, down 18.82% sequentially from $170000.0 in Q4 2025, and down 17.37% YoY from $167000.0 in Q1 2025.
Grace Therapeutics (GRCE) Interest & Investment Income (2019 - 2026) Analysis & Trends
Grace Therapeutics has reported Interest & Investment Income for 8 years, with the latest figure at $138000.0 in Q1 2026.
- Quarterly Interest & Investment Income fell 17.37% year-over-year to $138000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $685000.0 (down 3.79% YoY) and the FY2026 annual result came in at $685000.0, down 3.66% from the prior year.
- Interest & Investment Income retreated to $138000.0 in Q1 2026 per GRCE's latest filing, from $170000.0 in the prior quarter.
- Over five years, Interest & Investment Income peaked at $316000.0 in Q4 2023 and troughed at $32000.0 in Q2 2022.
- A 5-year average of $159687.5 and a median of $168500.0 in 2025 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2023 and 2024: Interest & Investment Income soared 488.89% in 2023, then plunged 56.33% in 2024.
- Over 5 years, Interest & Investment Income stood at $67000.0 in 2022, then surged by 371.64% to $316000.0 in 2023, then slumped by 56.33% to $138000.0 in 2024, then climbed by 23.19% to $170000.0 in 2025, then slipped by 18.82% to $138000.0 in 2026.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $138000.0, $170000.0, and $172000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Grace Therapeutics | 37.99 Mn | 37.99 Mn | - | 141,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 141,000.00 |
| Mar 31, 2026 | 138,000.00 |
| Dec 31, 2025 | 170,000.00 |
| Sep 30, 2025 | 172,000.00 |
| Jun 30, 2025 | 205,000.00 |
| Mar 31, 2025 | 167,000.00 |
| Dec 31, 2024 | 138,000.00 |
| Sep 30, 2024 | 172,000.00 |
| Jun 30, 2024 | 235,000.00 |
| Mar 31, 2024 | 249,000.00 |
| Dec 31, 2023 | 316,000.00 |
| Sep 30, 2023 | 212,000.00 |
| Jun 30, 2023 | 134,000.00 |
| Mar 31, 2023 | 112,000.00 |
| Dec 31, 2022 | 67,000.00 |
| Sep 30, 2022 | 36,000.00 |
| Jun 30, 2022 | 32,000.00 |
| Dec 31, 2021 | 40,000.00 |
| Sep 30, 2021 | 14,000.00 |
| Jun 30, 2021 | 20,000.00 |